Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus

Internal Medicine

Volumn 47, Issue 8, 2008, Pages 731-736

  Nagaishi, Akiko ^a,b   Yukitake, Motohiro ^a   Kuroda, Yasuo ^a  

^a SAGA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Corticosteroid; Immunotherapy; Myasthenia gravis; Prognosis; Tacrolimus; Treatment

Indexed keywords

PREDNISOLONE; PYRIDOSTIGMINE; TACROLIMUS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; HYPERLIPIDEMIA; LONG TERM CARE; LOW DRUG DOSE; MALE; MYASTHENIA GRAVIS; OBESITY; REMISSION; STEROID THERAPY; CLINICAL TRIAL; DRUG COMBINATION; LONGITUDINAL STUDY; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISOLONE; PROGNOSIS; TACROLIMUS;

EID: 44649146763     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0513     Document Type: Article

References (18)

1. Takamori M, Motomura M, Kawaguchi N, et al. Anti-rynodine receptor antibodies and FK506 in myasthenia gravis. Neurology 62: 1894-1896, 2004.
2. Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisolone-dependent myasthenia gravis. Neurology 64: 1641-1643, 2005.
3. Ponseti JM, Azem J, Fort JM, Cordina A, Montoro JB, Armengol M. Benefits of FK506 (tacrolimus) for residual, cyclosporine- and prednisolone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 107: 187-190, 2005.
4. Konishi T, Yoshimura Y, Takamori M, Saida T. Long-term treatment of generalized myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 76: 448-450, 2005.
5. Tada M, Shimohata T, Tada M, et al. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J Neurol Sci 247: 17-20, 2006.
6. Shimojima Y, Matsuda M, Gono T, Ishii W, Tokuda T, Ikeda S. Tacrolimus in refractory patients with myasthenia gravis: Coadministration and tapering of oral prednisolone. J Clin Neurosci 13: 39-44, 2006.
7. Wakata N, Saito T, Tanaka S, Hirano T, Oka K. Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 106: 5-8, 2003.
8. Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 9: 627-628, 2002.
9. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendation for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16-23, 2000.
10. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology 52: 1487-1489, 1999.
11. Kawaguchi N, Yoshikawa Y, Nemoto Y, Munakata S, Fukutake T, Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 20: 1269-1273, 2004.
12. Konishi T, Sanada M, Takehana K. Myasthenic crisis after the cession of FK506 in a patient with myasthenia gravis. J Neurol 251: 1154-1155, 2004.
13. Schneider-Gold C, Hartung H-P, Gold R. Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 34: 281-291, 2006.
14. Ning YM, Sanchez ER. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK 506 and repamycin. J Biol Chem 268: 6073-6076, 1993.
15. Davies TH, Ning YM, Sanchez ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP 51 and FKBP 52 immunophilins. J Biol Chem 277: 4597-4600, 2002.
16. Timerman AP, Ogubumni E, Freud E, Wiederrecht G, Marks AR, Fleischer S. The Calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. J Biol Chem 268: 22992-22999, 1993.
17. Mitsui T, Kunishige M, Ichiyama M, Shichijo K, Endo I, Matsumoto T. Benefical effect of tacrolimus on myasthenia gravis with thymoma. Neurologist 13: 83-86, 2007.
18. Nemoto Y, Kawaguchi N, Takahashi H, Munakata S, Hattori T. Analysis of cases of myasthenia gravis ceased to administer tacrolimus. Shinkeichiryougaku 24: 363, 2007 (abstract).